T-cell engager
Bispecific T-cell engager (BCMA × CD3)
- One arm binds a tumor antigen (BCMA), the other CD3 — the T cell is pulled onto the myeloma cell and activated
- Cytokine release syndrome and neurotoxicity are the mechanism’s cost; step-up dosing
- One arm binds a tumor antigen (BCMA), the other CD3 — the T cell is pulled onto the myeloma cell and activated
- Cytokine release syndrome and neurotoxicity are the mechanism’s cost; step-up dosing
Drugs with this mechanism (1)
- Linvoseltamab — BCMA×CD3 bispecific for relapsed myeloma; CRS and ICANS require step-up dosing.
All mechanisms · Open T-cell engager in the interactive console ↗